A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
Clinical trial NCT05503264 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05503264
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-27
- Primary completion
- 2026-12-16
- Enrollment
- 122
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.